Aprotinin for patients exposed to clopidogrel before Off-Pump coronary bypass

Asian Cardiovascular and Thoracic Annals

Volumn 16, Issue 6, 2008, Pages 483-487

  Nurözler, Feza ^a   Kutlu, Tolga ^a   Küçük, Güngör ^a  

^a Central Hospital Izmir   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CLOPIDOGREL; FRESH FROZEN PLASMA; PLACEBO;

ADULT; ANASTOMOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OFF PUMP CORONARY SURGERY; OUTCOME ASSESSMENT; PEROPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; REOPERATION; THORAX DRAINAGE; THROMBOCYTE TRANSFUSION; UNSTABLE ANGINA PECTORIS;

EID: 58249143517     PISSN: 02184923     EISSN: None     Source Type: Journal    
DOI: 10.1177/021849230801600611     Document Type: Article

References (20)

1. Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme: rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-41.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-900.
3. Nurozler F, Kutlu T, Küçük G, Okten C. Impact of clopidogrel on postoperative blood loss after non-elective coronary bypass surgery. Interact Cardiovasc Thorac Surg 2005;4:546-9.
4. Chen L, Bracey AW, Radovancevic R, Cooper JR Jr, Collard CD, Vaughn WK, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004;128:425-31.
5. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off pump and on pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002;359:1194-9.
6. Lemmer JH Jr, Dilling EW, Morton JR, Rich JB, Robicsek F, Bricker DL, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-67.
7. Poston RS, White C, Gu J, Brown J, Gammie J, Pierson RN, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006;81:104-10.
8. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005;30;112(Suppl I):276-80.
9. Nurozler F, Kutlu T, Küçük G, Okten C. Off-Pump coronary endarterectomy on high-risk patients. Asian Cardiovasc Thorac Ann 2006;14:227-30.
10. Walenga JM, Koza M, Hoppensteadt D, Sullivan H, Montoya A, Pifarré R. Fibrinolysis and the antifibrinolytic activity of aprotinin in cardiac surgery. In: Pifarré R. Blood conservation with aprotinin. Philadelphia: Hanley and Belfus, 1995:185-97.
11. Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824.
12. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
13. Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin. Thromb Haemost 1991;66:633-7.
14. Orchard MA, Goodchild CS, Prentice CR, Davies JA, Benoit SE, Creighton-Kemsford LJ, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993;85:533-41.
15. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 2000;120:370-8.
16. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004;110:2597-600.
17. Day JR, Haskard DO, Taylor KM, Landis RC. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Ann Thorac Surg 2006;81:619-24.
18. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004;84:579-621.
19. Casati V, Gerli C, Franco A, Della Valle P, Benussi S, Alfieri O, et al. Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology 2001;95:1103-9.
20. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg 2005;80:922-7.